中危和高危前列腺癌根治性治疗延迟的系统综述:延迟是否与更差结局相关?
该系统综述检索Medline、EMBASE和Cochrane数据库至2020年6月30日,纳入24篇文献,评估中危和高危局限性前列腺癌根治性治疗延迟对肿瘤学结局的影响。结果显示延迟至3个月对所有局限性前列腺癌是安全的,延迟超过6至9个月可能与生化复发和病理不良结局风险升高相关,但无癌特异性生存或总生存变差的报告。
要点
- 中危和高危局限性前列腺癌延迟根治性治疗至3个月不增加肿瘤学风险。
- 延迟超过6至9个月可能与生化复发和病理不良结局风险升高相关。
- 目前无证据显示治疗延迟导致癌特异性生存或总生存变差。
核心结论
- 中危和高危前列腺癌根治性治疗可延迟至3个月而无肿瘤学后果。
- 延迟超过6至9个月可能与生化复发和病理不良结局风险升高相关,但无生存变差报告。
研究设计与样本
- 系统综述检索Medline、EMBASE和Cochrane系统综述数据库,从建库至2020年6月30日。
- 共识别1793篇唯一参考文献,最终24篇符合数据提取标准,其中15篇发表于2013年之后。
主要发现
- 延迟至3个月对所有局限性前列腺癌是安全的,与更差肿瘤学结局无关。
- 部分研究报告延迟超过6至9个月与更差肿瘤学结局相关,但另有研究报告延迟至12个月无统计学显著关联。
- 发现更差结局的研究报告了更高的生化复发风险和更差的病理结局,但未报告更差的癌特异性生存或总生存。
临床怎么用
- 中危和高危局限性前列腺癌的根治性治疗可安全延迟至3个月。
- 应尽量避免治疗延迟超过6至9个月,以降低生化复发和病理不良结局风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Prostate cancer is most commonly an indolent disease, especially when detected at a localized stage. Unlike other tumors that may benefit from timely receipt of definitive therapy, it is generally accepted that treatment delays for localized prostate cancer are acceptable, especially for low risk prostate cancer. Since treatment delay for intermediate risk and high risk disease is more controversial, we sought to determine if delays for these disease states negatively impacted oncological outcomes. MATERIALS AND METHODS: We conducted a systematic review of the literature with searches of Medline, EMBASE and the Cochrane Database of Systematic Reviews from inception to June 30, 2020. General study characteristics as well as study population and delay information were collected. The outcomes of interest extracted included biochemical recurrence, pathological features (positive surgical margins, upgrading, extracapsular extension, and other pathological features), cancer specific survival and overall survival. RESULTS: After identifying 1,793 unique references, 24 manuscripts met criteria for data extraction, 15 of which were published after 2013. Based on our review, delays up to 3 months are safe for all localized prostate cancer and are not associated with worse oncological outcomes. Some studies identified worse oncological outcomes as a result of delays beyond 6 to 9 months. However, these studies are counterbalanced by others finding no statistically significant association with delays up to 12 months. Studies that did find worse outcomes as a result of delays identified a higher risk of biochemical recurrence and worse pathological outcomes but not worse cancer specific or overall survival. CONCLUSIONS: Definitive treatment for intermediate risk and high risk prostate cancer can be delayed up to 3 months without any oncological consequences. Some evidence suggests that there is a higher risk of biochemical recurrence and worse pathological outcomes associated with delays beyond 6 to 9 months. To date, there are no reports of worse cancer specific survival or overall survival as a result of delayed treatment for intermediate risk and high risk prostate cancer.
引用
- Nguyen DD, Haeuser L, Paciotti M, et al. Systematic Review of Time to Definitive Treatment for Intermediate Risk and High Risk Prostate Cancer: Are Delays Associated with Worse Outcomes? J Urol. 2021. PMID: 33443458. doi:10.1097/JU.0000000000001601
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。